Brief: Dimerix Says Taiba Acquires Exclusive Rights To Register, Commercialise DMX-200
27/05/2024 24:24
May 27 (Reuters) - Taiba Investments Company SJSC
4090.SE :
* TAIBA ACQUIRES EXCLUSIVE RIGHTS TO REGISTER AND
COMMERCIALISE
DMX-200 FOR TREATMENT OF FOCAL SEGMENTAL GLOMERULOSCLEROSIS
* EXCLUSIVE RIGHTS TO REGISTER DMX-200 IN UAE, SAUDI ARABIA,
OMAN,
KUWAIT, QATAR, BAHRAIN AND IRAQ
* DIMERIX TO RECEIVE UP TO ABOUT A$120.5 MILLION FROM TAIBA
IN
UPFRONT AND MILESTONE PAYMENTS
Further company coverage: 4090.SE
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Dimerix
See all newsAustralia's Dimerix soars on commercialisation deal with Everest Medicines
Brief: Dimerix Ltd Licenses Dmx200 To Everest For China And Asia Region
Brief: Everest Medicine In Agreement With Dimerix To Develop Commercialize DMX-200 In Greater China, South Korea, And Southeast Asia
Brief: Dimerix Seeks Trading Halt
Brief: Dimerix To Conduct Review Of Action3 Statistical Assumptions